Human Atrial Natriuretic Peptide/ANP Antibody

Detection of Human Atrial Natriuretic Peptide/ANP by Western Blot. Western blot shows lysates of iBJ6 human induced pluripotent stem cell line untreated (-) or differentiated to cardiomyoctyes (+). PVDF membrane was probed with 1 µg/mL of Goat Anti-Human Atrial Natriuretic Peptide/ANP Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3366) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for Atrial Natriuretic Peptide/ANP at approximately 17 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Atrial Natriuretic Peptide/ANP in BG01V Human Embryonic Stem Cells. Atrial Natriuretic Peptide/ANP was detected in immersion fixed BG01V human embryonic stem cells differentiated to cardiomyocytes using Goat Anti-Human Atrial Natriuretic Peptide/ANP Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3366) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Stem Cells on Coverslips.

Atrial Natriuretic Peptide/ANP in Human Prostate. Atrial Natriuretic Peptide/ANP was detected in immersion fixed paraffin-embedded sections of human prostate using Goat Anti-Human Atrial Natriuretic Peptide/ANP Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3366) at 3 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to stromal cells. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Detection of Human Atrial Natriuretic Peptide/ANP by Simple Western^TM. Simple Western lane view shows lysates of iBJ6 human induced pluripotent stem cell line untreated (-) or differentiated to cardiomyocytes (+), loaded at 0.2 mg/mL. A specific band was detected for Atrial Natriuretic Peptide/ANP at approximately 21 kDa (as indicated) using 10 µg/mL of Goat Anti-Human Atrial Natriuretic Peptide/ANP Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3366) followed by 1:50 dilution of HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

Detection of Human Atrial Natriuretic Peptide/ANP by Immunocytochemistry/Immunofluorescence Cardiac subtype-specific differentiation of WT and KCNA5fs/fs hiPSCs. (A) Illustration of directed differentiation protocol. Retinoic acid addition (RA, 0.5 μM) during the indicated time interval was used to selectively induce an atrial differentiation fate. (B) Subtype-specific cardiac differentiation showing RA-dependent suppression of ventricular gene expression (green) and induction of atrial markers (red) both in WT and KCNA5fs/fs hiPSCs (n = 2). Note the diminished KCNA5 expression level in RA-treated mutant cardiomyocytes. (C) Immunocytochemical staining of Kv1.5 (top), atrial natruretic peptide, and ventricular-specific myosin light chain 2 (bottom). Note that the MLC2v staining appears relatively weak and diffuse due to the early time-point of analysis (2.5 week after differentiation start). Image collected and cropped by CiteAb from the following publication (https://journal.frontiersin.org/article/10.3389/fphys.2017.00469/full), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human Atrial Natriuretic Peptide/ANP by Immunocytochemistry/Immunofluorescence EOMES programs hESCs into functional CMs at high efficiency. a Illustration of growth factor-mediated and optimized EOMES induction-based cardiac differentiation protocols. Bottom right: Immunoblot validating doxycycline-dependent EOMES expression in a transgenic EOMESKO/E.TET-ON hESC line. b Typical yields of hESC-CMs (left, flow cytometry) and NKX2.5 expression (right, immunoblot) obtained with the two protocols (day 10). c Immunostainings 21 days after the initiation of EOMES induction. Weak perinuclear ANP staining is typical in overall MLC2v-positive hESC-CMs. Scale bars: 25 (top) and 50 µm (bottom). d Acceleration and slowdown of spontaneous beat rates in pCMs following exposure to 10 µM isoprenaline and 10 µM propranolol, respectively, on multielectrode arrays. e Microarray-based time course analysis comparing the indicated protocols and cell lines. RESCUE cells carry an inducible EOMES transgene on EOMESKO HuES6 background. Underlying data are from Supplementary Data 2 Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29382828), licensed under a CC-BY license. Not internally tested by R&D Systems.